Building bridges and learning about the latest in interventional neurovascular technology at the SVIN 2016

Share

T3 Labs will be present at the Society of Vascular and Interventional Neurology (SVIN) annual meeting, which will be held November 16 – 19, 2016 in Brooklyn, New York. This is a great opportunity to learn about the latest clinical and scientific contributions in endovascular technologies and innovative approaches in the management of stroke and other neurological disorders. As an industry leading preclinical CRO, these leading events are the core for innovation, diversification and improved service for our customer’s challenges at T3 Labs.

Among the presentations offered this year, we at T3 Labs are especially interested in:

Session 1: “Aneurysm management”, dedicated to the use of flow diverters as extra-saccular adjunctive devices for treating aneurysms.

Session 7: “Stroke: What’s Next?”, featuring Dr. Lucas Elijovich describing the “Stroke Neurointerventional Suite of the Future” and New Stroke Devices.”

Last but not least, Session 9: Emerging Technologies, showcasing “New Intravascular Devices” with Dr. Nirav Vora and the “ICH Mini Symposium” with Dr. D. Fiorella and others.

You can view the full conference program and agenda here.

Since January 2012, T3 Labs has archived more than 50 GLP studies from which more than 30 products have received regulatory approval. From concept to cure to commercialization, we pride ourselves on precision, quality, access and service for every single one of our preclinical testing and bioskills training sponsors.

In our sponsors’ own words:

“Our experience with T3 Labs created new knowledge and refinements to the device that resulted in a product that was highly mature at the time we started our clinical trials in humans.” – St. Jude Medical

“Being confident that our preclinical CRO partner T3 Labs delivers thorough GLP reports that generate regulatory clearances as swiftly as possible is immensely valuable to us.” – Surefire Medical

The annual SVIN conference allows participants to not only get acquainted with the latest advancements in interventional treatment of neurovascular diseases, it enables them to connect with friends and colleagues, both old and new, sharing their latest endeavors. T3 Labs will be part of this camaraderie at SVIN 2016; interacting with experts in the field, industry partners, endovascular practitioners, interventional neurologists and residents, and building bridges for new collaborations.

Our bags are packed. Let’s connect in Brooklyn!

If you are a physician innovator with a ‘back of the napkin’ idea for a new endovascular device, a medical device company of any shape or size evaluating a new product’s readiness for preclinical, or if you just want to talk about the latest in endovascular and neurovascular technologies, contact Liliana Cesar, Program Managervia email, liliana.cesar@t3labs.org, to schedule an onsite meeting at SVIN 2016.